Melanotan I
Melanotan I is a synthetic analogue of alpha-melanocyte-stimulating hormone (alpha-MSH) that acts primarily at the melanocortin-1 receptor (MC1R). Its pharmaceutical form, afamelanotide (brand name Scenesse), is a controlled-release subcutaneous implant that has received regulatory approval in some regions, including the EU and the United States, for use in adults with the rare genetic condition erythropoietic protoporphyria (EPP). That approval is narrow: it covers a specific implant product, a specific indication, and clinician administration. Gray-market material sold as "Melanotan 1" for tanning or other purposes is a separate, unapproved research chemical and should not be conflated with the approved implant.
Side effects & risks
Reported and studied adverse effects of melanocortin agonists in this class include nausea, facial flushing, headache, and fatigue, most commonly noted early in exposure. Generalized darkening of the skin and, importantly, darkening or change in existing moles and freckles is a recognized effect and a key safety concern. Because these compounds can alter melanocytic lesions, monitoring of moles and skin lesions is emphasized, and any new, changing, or asymmetric lesion warrants prompt dermatological evaluation. Injection-site or implant-site reactions have been reported with the relevant delivery routes. Gray-market injectable material carries additional risks including unknown purity, contamination, and dosing errors that are absent from the approved, clinician-administered implant. This compound is not appropriate for people with a personal or family history of melanoma or significant atypical nevi without specialist input, and anyone with numerous or atypical moles should exercise particular caution. Use of any material in this class should involve a clinician and, given the pigmentary effects, baseline and ongoing dermatology review.
Latest studies
Afamelanotide improves quality of life and light tolerance in Austrian erythropoietic protoporphyria patients.
A real-world study of 20 Austrian patients found that afamelanotide (melanotan-1) was associated with markedly longer pain-free sun exposure, better quality of life, and fewer phototoxic reactions in erythropoietic protoporphyria.
Insights into Tanning Biology and Tanning Products.
A systematic review of self-tanning agents reports that unregulated melanotan use has been associated with serious adverse effects including rhabdomyolysis, renal infarction, and priapism.
Polymorphism of Melanocortin Receptor Genes-Association with Inflammatory Traits and Diseases.
Melanocortin receptors are a family of five cell-surface receptors (MC1R through MC5R) involved in a surprisingly wide range of jobs: skin pigmentation, appetite and energy balance, stress hormones, mood, and immune signalling. This review summarizes how inherited variations in the genes for these receptors are linked to different conditions — for example, MC1R variants with melanoma risk, MC4R variants with obesity and type 2 diabetes, and several receptors with depression. It also describes the receptors' roles in inflammatory diseases such as eczema, autoimmune eye inflammation, multiple sclerosis, and inflammatory bowel disease, and notes that drugs targeting this system are being explored as anti-inflammatory agents. The authors point to several approved melanocortin drugs as proof the receptor family can be targeted, including bremelanotide (for low sexual desire in women), afamelanotide, and setmelanotide (for certain forms of obesity). Bremelanotide is mentioned only as one example among these approved drugs; the article does not test it or report how well it works. This is a broad overview of receptor biology and genetics, not a study of any single medication.
Reported protocols (with caveats)
In its approved form, afamelanotide is a subcutaneous implant inserted by a healthcare professional, typically dosed at intervals of several weeks during periods of higher light exposure, strictly within the EPP indication and clinical supervision. This is the only administration route with regulatory approval and should be directed by a clinician. Separately, gray-market "Melanotan 1" is reported in community and research-use-only contexts as a reconstituted subcutaneous injection, with reported protocols describing a short daily loading phase followed by less frequent maintenance dosing. These reported figures come from user reports and non-clinical sources, not controlled trials, and vary widely. Such gray-market use is research use only and is not recommended; no self-administered protocol here should be read as guidance.